1. Show article details.

    Theravance to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference

    Market Wire – 4:05 PM ET 05/07/2015

    05/07/15 -- Theravance, Inc. (THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Healthcare Conference on Wednesday, May 13, 2015 at 1:00 p.m. PDT.

  2. Show article details.

    Theravance Reports First Quarter 2015 Financial Results

    Market Wire – 4:05 PM ET 05/06/2015

    05/06/15 -- Theravance, Inc. (THRX) today reported financial results for the first quarter ended March 31, 2015. Theravance (THRX) also announced that the company's Board of Directors has declared a $0.25 per share cash dividend to be paid on June 30, 2015 to stockholders of record as of the close of business on June 12, 2015.

  3. Show article details.

    U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug

    Reuters – 11:18 AM ET 05/01/2015

    The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc (THRX) said. The FDA declined to approve Breo for younger asthma sufferers. The FDA's decision came after an FDA advisory panel of experts had voted 16-4 that Breo Ellipta should be approved for use by adults.

  4. Show article details.

    U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug

    Reuters – 5:31 PM ET 04/30/2015

    The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc (THRX) said. The FDA declined to approve Breo for younger asthma sufferers. The FDA's decision came after an FDA advisory panel of experts had voted 16-4 that Breo Ellipta should be approved for use by adults.

  5. Show article details.

    FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US

    PR Newswire – 4:36 PM ET 04/30/2015

    LONDON and SAN FRANCISCO, April 30, 2015GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced that the US Food and Drug Administration has approved BREO® ELLIPTA® for the once-daily treatment of asthma in patients aged 18 years and older. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol.

  6. Show article details.

    FDA Approves BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma in the US

    Market Wire – 3:17 PM ET 04/30/2015

    04/30/15 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced that the US Food and Drug Administration has approved BREO® ELLIPTA® for the once-daily treatment of asthma in patients aged 18 years and older. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol.

  7. Show article details.

    Theravance to Report First Quarter 2015 Financial Results on May 6, 2015

    Market Wire – 4:05 PM ET 04/29/2015

    04/29/15 -- Theravance, Inc. (THRX) announced today that it will report financial results for the first quarter ended March 31, 2015 after market close on Wednesday, May 6, 2015. To participate in the live call by telephone, please dial 837-3908 from the U.S., or 890-8166 for international callers.

  8. Show article details.

    GSK and Theravance Announce Outcome of US FDA Advisory Committee on BREO(R) ELLIPTA(R) in Asthma

    Market Wire – 5:55 PM ET 03/19/2015

    03/19/15 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States Food and Drug Administration regarding the supplemental New Drug Application for BREO® ELLIPTA® as a once-daily inhaled treatment for asthma in patients aged 12 years ...

  9. Show article details.

    Theravance Announces Trading in Common Stock Halted

    Market Wire – 7:05 AM ET 03/19/2015

    03/19/15 -- Theravance, Inc. (THRX) announced today that NASDAQ halted trading of the Company's common stock this morning, March 19, 2015. BREO® ELLIPTA® is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist vilanterol, administered using the ELLIPTA® inhaler.

  10. Show article details.

    Theravance to Present at the Cowen Healthcare Conference

    Market Wire – 4:05 PM ET 02/25/2015

    02/25/15 -- Theravance, Inc. (THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, is scheduled to present at the Cowen Healthcare Conference on Wednesday, March 4, 2015, at 9:20 a.m. EST.

  11. Show article details.

    Theravance, Inc. Announces Cash Dividend of $0.25 per Share Payable to Stockholders of Record as of March 12, 2015

    Market Wire – 4:05 PM ET 02/23/2015

    02/23/15 -- Theravance, Inc. (THRX) today announced that the company's Board of Directors has declared a $0.25 per share cash dividend to be paid on March 31, 2015 to stockholders of record as of the close of business on March 12, 2015.

  12. Show article details.

    Theravance Reports Fourth Quarter and Full Year 2014 Financial Results

    Market Wire – 4:17 PM ET 02/18/2015

    02/18/15 -- Theravance, Inc. (THRX) today reported financial results for the quarter and year ended December 31, 2014.

  13. Show article details.

    Theravance to Report Fourth Quarter and Full Year 2014 Financial Results on February 18, 2015

    Market Wire – 4:05 PM ET 02/11/2015

    02/11/15 -- Theravance, Inc. (THRX) announced today that it will release financial results for the fourth quarter and full year ended December 31, 2014 after market close on Wednesday, February 18, 2015. An accompanying conference call will be held at 5:00 p.m. Eastern Standard Time. A replay of the conference call will be available on Theravance's (THRX) website for 30 days through March 20, 2015.

  14. Show article details.

    GSK and Theravance Announce Start of Phase III Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI for COPD

    Market Wire – 5:10 AM ET 02/09/2015

    02/09/15 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) today announced the start of a second global phase III study to evaluate the effects of the investigational once-daily closed triple combination of fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease.

  15. Show article details.

    Theravance Announces FDA Advisory Committee to Review BREO(R) ELLIPTA(R) (FF/VI) for Asthma

    Market Wire – 9:10 AM ET 02/06/2015

    02/06/15 -- Theravance, Inc. (THRX) today announced that on March 19, 2015, the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will discuss the supplemental New Drug Application 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation, sponsored by Glaxo Group Limited for the once-daily treatmen...

  16. Show article details.

    Theravance to Present at the Leerink Global Healthcare Conference

    Market Wire – 4:05 PM ET 02/05/2015

    02/05/15 -- Theravance, Inc. (THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 11:10 a.m. EST.

Page:

Today's and Upcoming Events

  • Aug
    6

    THRX to announce Q2 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Jun
    10

    THRX ex-Dividend for $0.25 on 6/10/2015

    • Announce Date: 5/6/2015
    • Record Date: 6/12/2015
    • Pay Date: 6/30/2015
  • May
    6

    THRX Earnings Conference Call at 5:00 PM Listen

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.